Allogene Scraps Immunosuppressive Antibody After Patient Death in Lymphoma Trial
The pivotal Phase II trial is testing Allogene’s CAR T candidate cemacabtagene ansegedleucel for large B-cell lymphoma. ALLO-647 was being used as a preparative lymphodepletion therapy.Read more:
biospace.comBiotechnology